Chest
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Acute exacerbations (AEs) have a negative impact on various aspects of the progression of COPD, but objective and detailed data on the impact of hospitalizations for an AE on physical activity are needed. This study was designed to evaluate the levels of activity during hospitalization in adults with acute exacerbation of COPD. ⋯ The following authors have nothing to disclose: Marie Carmen Valenza, Irene Torres-Sánchez, Gerald Valenza-Demet, Irene Cabrera-Martos, Maria José Flores-Barba, Maria Angustias AcostaNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: Primary pulmonary hypertension is severe and progressive disease with incidence of 1-2 cases / million / annum. Without treatment, survival is 2-3 years. Only 10% survive for 10 years. Co-existence of PPH with Marfanoid Habitus has not been reported till date in any literature or case study.Large series of 120 PPH patients from Mayo clinic by Fuster et al showed thrombotic mechanism by microemboli and plexogenic arteriopathy due to hyper reactive pulmonary arteries by open lung biopsies. ⋯ The following authors have nothing to disclose: Ram k Chopra, Sanesh Garde, Chintan Patel, Dhiraj Jain, Omkar Kajale, Rahul JalanNo Product/Research Disclosure Information.
-
Sleep PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: AIMS 1-To study the effect of the growth pattern in the treatment of SAHS by a MAD by the use of polysomnographic recordings. 2-To determine the effect of the growth pattern on the position of the hyoid bone in the SAHS treatment by a MAD. ⋯ The following authors have nothing to disclose: Rafael Ecija, Javier Jareño, Alejandro Coca, Inmaculada Sierra, Marta Dominguez, Carlos Gutierrez OrtegaNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the long-term effect of riociguat in PAH patients in FC I/II versus FC III/IV at PATENT-1 baseline. ⋯ Gisela Meyer: Consultant fee, speaker bureau, advisory committee, etc.: Gisela Meyer has received advisory board and speaker fees from Bayer, Lilly and GlaxoSmithKline. Nazzareno Galiè: Grant monies (from industry related sources): Nazzareno Galiè received grant money paid to his institution by Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Nazzareno Galiè received consulting fees, honorariums and/or support for travel to meetings from Bayer. Friedrich Grimminger: Grant monies (from industry related sources): Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Friedrich Grimminger has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare. Ekkehard Grünig: Consultant fee, speaker bureau, advisory committee, etc.: Ekkehard Grünig received support for travel to meetings from Bayer Pharma. Marc Humbert: Consultant fee, speaker bureau, advisory committee, etc.: Marc Humbert has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Zhi-Cheng Jing: Consultant fee, speaker bureau, advisory committee, etc.: Zhi-Cheng Jing has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Anne M. Keogh: Grant monies (from industry related sources): Anne M. Keogh has received grant money paid to her institution from Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Anne M. Keogh has received consultancy fees from Bayer. David Langleben: Grant monies (from industry related sources): David Langleben received grant money paid to his institution from Bayer Inc., Consultant fee, speaker bureau, advisory committee, etc.: David Langleben received consulting fees/honorarium, paid to his institution by Bayer Inc., Other: David Langleben received fees for participation in review activities, paid to his institution by Bayer Inc. Lewis J Rubin: Consultant fee, speaker bureau, advisory committee, etc.: Lewis J. Rubin has received consulting fees, honorarium and/or support for travel to meetings from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia., Other: Lewis J. Rubin has received fees for participation in review activities from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia. Arno Fritsch: Shareholder: Arno Fritsch has received stock/stock options from Bayer HealthCare., Employee: Arno Fritsch is a full-time employee of Bayer HealthCare. Neil Davie: Employee: Neil Davie is a full-time employee of Bayer HealthCare. Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources): Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Hossein-Ardeschir Ghofrani has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare.Riociguat is an investigational new drug currently in process for registration submission to health authorities, after successful finalisation of a RCT in patients with PAH.
-
Surgery Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Radical chest wall tumor resections result in large chest wall defects that expose intrathoracic organs to injury, risk lung herniation or scapular entrapment, and create flail chest segments that negatively impact respiration. ⋯ The following authors have nothing to disclose: Eric Toloza, Christian Sobky, Jose Pimiento, Joseph Garrett, Effie Pappas-Politis, Jeremiah Deneve, David Kim, David Plank, Paul Smith, Ricardo GonzalezUse of the Synthes MatrixRib Fixation System is not yet approved for fixation onto the thoracic spine.